<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36163089</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Internet"><Volume>178</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev Neurol (Paris)</ISOAbbreviation></Journal><ArticleTitle>Epidemiological time-trend of amyotrophic lateral sclerosis (ALS) over two decades: The French population-based register of ALS in Limousin (FRALim register).</ArticleTitle><Pagination><StartPage>914</StartPage><EndPage>923</EndPage><MedlinePgn>914-923</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2022.05.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0035-3787(22)00721-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Population-based registers are key to understanding disease patterns. Taking advantage of the long-standing operation of the French register of amyotrophic lateral sclerosis (ALS) in Limousin (FRALim register), we sought to determine the time trends in incidence, clinical features and survival of ALS patients from 2000 to 2020.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">FRALim register included incident cases through multiple sources of ascertainment. A capture-recapture method was used to assess the exhaustiveness of case ascertainment. Crude and standardized incidences were calculated per 100,000 person-years of follow-up (PYFU). Time-period was divided (period 2000 to 2010 and period 2011 to 2020) to compare incidence rates and clinical features. Survival was analyzed using Kaplan-Meier method. Cox proportional hazards model was performed to calculate hazards for the time periods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 501 incident cases were identified during 21 years. The overall crude incidence was 3.26 (95% CI 2.97 to 3.55) per 100&#xa0;000 PYFU. The exhaustiveness of the register was estimated at 98.8% (95% CI 97.4-99.6%) by capture-recapture analysis. Several fluctuations were observed without a consistent trend over the last two decades. The crude and standardized incidences were higher in males than females. The peak of incidence was observed in the 75-79 years age band. Almost one-third of the cases exhibited a bulbar onset. There were significant differences in clinical features between time periods. Four hundred and ninety-one cases were included in the survival analysis. The median survival time from diagnosis was 16.0 months (95% CI 14.3 to 17.7 months). Patients in the last decade experienced a lower risk of dying but the difference did not reach statistical significance (adjusted HR: 0.89 (95% CI 0.73 to 1.08, P=0.229).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We provided reliable epidemiological data over two decades. We showed that incidence has been relatively stable, while clinical variability was observed. A slight improvement in survival time was found in the last decade but it was not statistically significant. Further quality register data are needed to improve our understanding of ALS epidemiological trends.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luna</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Inserm U1094, IRD U270, EpiMaCT&#xa0;-&#xa0;Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, University Limoges, CHU de Limoges, Limoges, France; Department of Neurology, Centre de R&#xe9;f&#xe9;rence SLA et autres maladies du neurone moteur, CHU de Limoges, Limoges, France; European Reference Network for Rare Neuromuscular Diseases (EURO-NMD) Health Care Providers (HCP) Limoges Tours, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defressigne</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Inserm U1094, IRD U270, EpiMaCT&#xa0;-&#xa0;Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, University Limoges, CHU de Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erazo</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Inserm U1094, IRD U270, EpiMaCT&#xa0;-&#xa0;Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, University Limoges, CHU de Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lautrette</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Centre de R&#xe9;f&#xe9;rence SLA et autres maladies du neurone moteur, CHU de Limoges, Limoges, France; European Reference Network for Rare Neuromuscular Diseases (EURO-NMD) Health Care Providers (HCP) Limoges Tours, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raymondeau-Moustafa</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre d'&#xc9;pid&#xe9;miologie de Biostatistique et de M&#xe9;thodologie de la Recherche, CHU Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preux</LastName><ForeName>P-M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Inserm U1094, IRD U270, EpiMaCT&#xa0;-&#xa0;Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, University Limoges, CHU de Limoges, Limoges, France; Centre d'&#xc9;pid&#xe9;miologie de Biostatistique et de M&#xe9;thodologie de la Recherche, CHU Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boumediene</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Inserm U1094, IRD U270, EpiMaCT&#xa0;-&#xa0;Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, University Limoges, CHU de Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Inserm U1094, IRD U270, EpiMaCT&#xa0;-&#xa0;Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, University Limoges, CHU de Limoges, Limoges, France; Department of Neurology, Centre de R&#xe9;f&#xe9;rence SLA et autres maladies du neurone moteur, CHU de Limoges, Limoges, France; European Reference Network for Rare Neuromuscular Diseases (EURO-NMD) Health Care Providers (HCP) Limoges Tours, Limoges, France. Electronic address: philippe.couratier@unilim.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Clinical</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Population-based</Keyword><Keyword MajorTopicYN="N">Register</Keyword><Keyword MajorTopicYN="N">Survival</Keyword><Keyword MajorTopicYN="N">Trend</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>26</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36163089</ArticleId><ArticleId IdType="doi">10.1016/j.neurol.2022.05.004</ArticleId><ArticleId IdType="pii">S0035-3787(22)00721-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>